This excerpt taken from the LDIS 8-K filed Jan 26, 2006.
Item 7.01 Regulation FD Disclosure.
On January 23, 2006, Leadis issued a press release announcing (i) the hiring of Dr. Jose Arreola as Executive Vice President, Engineering and (ii) the resignation of Dr. Steve Ahn as an officer of the company effective in February. Dr. Ahn will remain a member of the Leadis Board of Directors and will also serve as an advisor to Leadis.
A copy of the press release announcing these management changes is attached hereto as Exhibit 99.2 to this current report and is incorporated herein by reference.
This excerpt taken from the LDIS 8-K filed Dec 22, 2005.
Item 7.01 Regulation FD Disclosure.
On December 22, 2005, Leadis Technology, Inc. (the Company) issued a press release announcing the Companys revised financial guidance for the fourth quarter ended December 31, 2005. A copy of the press release is attached hereto as Exhibit 99.1 to this current report and is incorporated herein by reference.
The information in the report, including the exhibit hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, except as expressly set forth by specific reference in such a filing.
This excerpt taken from the LDIS 8-K filed Aug 25, 2005.
Item 7.01 Regulation FD Disclosure
Leadis Technology, Inc. has been informed by Steve Ahn, its President and Chief Executive Officer, and Ken Lee, its Executive Vice President and Chief Operating Officer, that each has adopted a pre-arranged stock trading plan to sell a portion of his company stock over time as part of his individual long-term strategy for asset diversification and liquidity. The stock trading plans were adopted in accordance with guidelines specified under Rule 10b5-1 of the Securities and Exchange Act of 1934 and Leadis Technologys policies regarding stock transactions. The shares that may be sold pursuant to these plans represent less than 20% of Dr. Ahns holdings and less than 15% of Dr. Lees holdings of Leadis Technology securities. The plans will terminate on or before June 9, 2006. Certain other of Leadis Technologys officers and directors may adopt Rule 10b5-1 plans in which they will contract with a broker to exercise and sell options or sell shares on a periodic basis.
Rule 10b5-1 allows persons who may be considered insiders to adopt pre-arranged written plans for trading specified amounts of company stock when they are not in possession of material nonpublic information. Once established, the insider retains no discretion over purchases and sales under a Rule 10b5-1 plan. The pre-arranged trades may then be executed through a broker at later dates without regard to any subsequent material non-public information that the insider may receive. By using these plans, insiders can gradually diversify their investment portfolios, spread stock trades out over an extended period of time to reduce market impact and avoid concerns about potentially having material, non-public information when they sold their stock. Transactions made under Dr. Ahns and Dr. Lees plans will be disclosed publicly through Form 4 filings made with the Securities and Exchange Commission. In addition, transactions will be subject to the restrictions mandated by Rule 144 of the U.S. Securities Act of 1933, as amended.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.